Fig. 2: Association between neoadjuvant treatment and survival according to mismatch repair (MMR) status.

a Disease-free survival (DFS), and b distant metastasis-free survival (DMFS) in patients with deficient MMR (dMMR) by neoadjuvant radiotherapy. c DFS and d Local recurrence-free survival (LRFS) in patients with stage III disease and proficient MMR (pMMR) tumors by neoadjuvant radiotherapy. NCT neoadjuvant chemotherapy, NCRT neoadjuvant chemoradiotherapy, HR hazard ratio, CI confidential interval.